Oarsman Capital’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$628K Sell
4,006
-314
-7% -$47.1K 0.07% 123
2026
Q1
$660K Sell
4,320
-110
-2% -$16.9K 0.08% 123
2025
Q4
$611K Sell
4,430
-349
-7% -$45.7K 0.08% 130
2025
Q3
$613K Sell
4,779
-295
-6% -$36K 0.09% 125
2025
Q2
$614K Sell
5,074
-285
-5% -$32.1K 0.1% 128
2025
Q1
$597K Sell
5,359
-240
-4% -$25.6K 0.11% 122
2024
Q4
$545K Sell
5,599
-228
-4% -$24.3K 0.09% 126
2024
Q3
$670K Sell
5,827
-33
-0.6% -$3.74K 0.12% 114
2024
Q2
$624K Sell
5,860
-327
-5% -$32.8K 0.14% 106
2024
Q1
$598K Sell
6,187
-128
-2% -$13.1K 0.14% 109
2023
Q4
$638K Buy
6,315
+98
+2% +$9.46K 0.17% 108
2023
Q3
$633K Sell
6,217
-65
-1% -$6.6K 0.26% 89
2023
Q2
$634K Sell
6,282
-195
-3% -$19.5K 0.28% 84
2023
Q1
$596K Sell
6,477
-315
-5% -$27.5K 0.28% 84
2022
Q4
$616K Sell
6,792
-365
-5% -$30.7K 0.31% 79
2022
Q3
$544K Sell
7,157
-235
-3% -$19.5K 0.29% 88
2022
Q2
$625K Sell
7,392
-690
-9% -$60.5K 0.31% 85
2022
Q1
$709K Buy
8,082
+550
+7% +$47.6K 0.28% 95
2021
Q4
$659K Sell
7,532
-795
-10% -$66K 0.26% 98
2021
Q3
$681K Sell
8,327
-405
-5% -$36.4K 0.28% 99
2021
Q2
$797K Sell
8,732
-10,319
-54% -$919K 0.32% 94
2021
Q1
$1.63M Sell
19,051
-5,017
-21% -$450K 0.7% 46
2020
Q4
$2.27M Sell
24,068
-266
-1% -$23.2K 0.88% 34
2020
Q3
$2.12M Sell
24,334
-2,415
-9% -$209K 0.95% 29
2020
Q2
$2.34M Buy
26,749
+15,234
+132% +$1.31M 1.15% 23
2020
Q1
$949K Sell
11,515
-10,622
-48% -$948K 0.88% 39
2019
Q4
$2.1M Buy
22,137
+9,447
+74% +$848K 0.96% 32
2019
Q3
$1.1M Sell
12,690
-150
-1% -$13.5K 0.52% 65
2019
Q2
$1.17M Sell
12,840
-1,510
-11% -$128K 0.53% 67
2019
Q1
$1.24M Sell
14,350
-334
-2% -$26.8K 0.59% 61
2018
Q4
$1.13M Sell
14,684
-157
-1% -$12.2K 0.58% 65
2018
Q3
$1.15M Sell
14,841
-279
-2% -$20.6K 0.46% 72
2018
Q2
$1.02M Buy
15,120
+1,835
+14% +$127K 0.46% 76
2018
Q1
$962K Buy
13,285
+122
+0.9% +$9.29K 0.44% 75
2017
Q4
$990K Sell
13,163
-184
-1% -$13.9K 0.43% 75
2017
Q3
$1.03M Sell
13,347
-257
-2% -$19.4K 0.43% 74
2017
Q2
$1.02M Sell
13,604
-352
-3% -$24.9K 0.47% 73
2017
Q1
$929K Sell
13,956
-1,015
-7% -$67.6K 0.43% 76
2016
Q4
$977K Sell
14,971
-2,701
-15% -$175K 0.63% 51
2016
Q3
$1.25M Sell
17,672
-673
-4% -$49K 0.64% 53
2016
Q2
$1.36M Sell
18,345
-543
-3% -$37.5K 0.7% 48
2016
Q1
$1.23M Buy
18,888
+16
+0.1% +$1.09K 0.65% 52
2015
Q4
$1.46M Buy
18,872
+95
+0.5% +$7.55K 0.81% 43
2015
Q3
$1.55M Buy
18,777
+23
+0.1% +$2.05K 0.91% 36
2015
Q2
$1.65M Sell
18,754
-318
-2% -$29.2K 1.13% 24
2015
Q1
$1.69M Sell
19,072
-56
-0.3% -$4.97K 1.16% 22
2014
Q4
$1.59M Sell
19,128
-235
-1% -$19.5K 1.14% 23
2014
Q3
$1.63M Buy
19,363
+62
+0.3% +$5.02K 1.2% 19
2014
Q2
$1.57M Sell
19,301
-23
-0.1% -$1.81K 1.14% 23
2014
Q1
$1.47M Sell
19,324
-228
-1% -$16.6K 1.14% 24
2013
Q4
$1.41M Buy
19,552
+83
+0.4% +$5.77K 1.13% 25
2013
Q3
$1.34M Buy
19,469
+441
+2% +$29.2K 1.17% 23
2013
Q2
$1.21M Buy
+19,028
New +$1.24M 1.14% 25

Other funds holding NVS

Oarsman Capital's NVS Position: Q2 2026 in Review

Oarsman Capital reduced its Novartis (NVS) stake by 7.3% in Q2 2026, selling an estimated $47.1K and leaving 4,006 shares worth $628K. The position accounts for 0.07% of the portfolio, ranked #123.

Oarsman Capital first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.34M in Q2 2020. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Oarsman Capital held 4,006 shares of Novartis worth $628K as of Q2 2026.
  • Oarsman Capital sold 314 Novartis shares in Q2 2026, an estimated $47.1K.
  • Novartis made up 0.07% of Oarsman Capital's portfolio in Q2 2026, its #123 holding.
  • Oarsman Capital first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Oarsman Capital's Novartis position peaked at $2.34M in Q2 2020.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Oarsman Capital's 13F filing for Q2 2026, filed 7 Aug 2026.